Die Regulation der ANP-Freisetzung  bei HerzinsuffizienzAngela Nikola Model1.11.121.1.13451.1.2671.1.381.1.491.210419#3811.2.11112131.2.214151.2.31.2.3.1317#3241.2.3.21617181.2.3.31.3192.2.1202.221399#3152.3222.42.4.12324471#5482.4.22.4.32526563#2062728610#228292.52.5.12.5.22.5.330365#232.6313.3.13.1.13132432#3683.1.2355#30933312#2573.1.334392#2953.1.435306#270306#2773.23.2.136455#35937362#3363.2.238584#41939352#3203.2.340490#37441396#3323.33.3.142537#2593.3.24344590#2473.3.34546613#2894.4.146474.1.1484.1.2495051524.1.34.1.4534.2544.2.15556574.2.24.2.3584.3594.3.1604.3.26162635.6364 Abkürzungen LITERATURVERZEICHNISDANKSAGUNGERKLÄRUNG AN EIDES STATTLEBENSLAUFdeInhaltsverzeichnisHilfe LITERATURVERZEICHNIS 1 Braunwald E, Hauci AS, Kasper DL, et al.: Harrisons Innere Medizin Band 1 (deutsche Auflage in Zusammenarbeit mit der Charité). Mc Graw-Hill ABW Wissenschaftsverlag GmbH. 2003; 1451-1456 . 2 Statistisches Bundesamt Deutschland: Sterbefälle nach den 10 häufigsten Todesursachen 2001. Francis GS: Am J Med. 2001; 110(7A): 37S-46S 4 Ho KKL, Anderson KM, Kannel WB, et al.: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993; 88: 107-115. 5 Ho KKL, Pinsky JL, Kannel WB, et al.: The epidemiology of heart failure. The Framingham Study. J Am Coll Cardiol.1993; 22: 6A-13A. 6 Braunwald E, Zipes DP, Libby P: Heart Disease: A Textbook of Cardiovascular Medicine (6th Edition) . W.B. Saunders Company.

Philadelphia, London, New York, St. Louis, Sydney, Toronto.

2001;

503-533. 7 ter Keurs HE: Heart failure and Starling´s Law of the Heart. Can J Cardiol. 1996; 12(10): 1047-1057. 8 Grossman W, Jones D, McLaurin LP: Wall stress patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975; 56 56-5664. 9 Anversa P, Ricci R, Olivetti R: Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review. J Am Coll Cardiol. 1987; 7: 1140-1149. 10 St. John Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation. 2000; 101: 2981-2988. 11 Piano MR, Bondmass M, Schwertz DW: The molecular and cellular pathophysiology of heart failure. Heart Lung. 1998; 27:3-19. 12 Morkin E: Postnatal muscle fiber assembly: localisation of newly synthesized myofibrillar proteins. Science. 1970; 167: 1499-1501. 13 Gerdes AM, Campbell SE, Hilbelink DR: Structural remodeling of cardiac myocytes in rats with ateriovenous fistulas. Lab Invest. 1988; 59 857-59861 . 14 Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the framingham study. Ann Intern Med. 1969; 71: 89-105. 15 Levy D, Garrison RJ, Savage D, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561-1566. Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001; 141: 334-341. 17 Sussman MA, McCulloch A, Borg TK: Dance Band on the Titanic: Biomechanical Signaling in Cardiac Hypertrophy. Circ Res. 2002; 91: 888-898. 18 Log CS, Kariya K, Karns L, et al.: Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol. 1991; 17(suppl2): S20-S24. 19 Simpson PC, Kariya K, Karns LR, et al.: Adrenergic hormones and control of cardiac myocyte growth. Mol Cell Biochem. 1991; 104: 35-43. 20 Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest. 1990; 85: 507-514. 21 Parker TG, Chow KL, Schwartz RJ, et al.: Positive and negative control of the skeletal alpha-actin promoter in cardiac muscle. A proximal serum response element is sufficient for induction by basic fibroblast growth factor (FGF) but not for inhibition by acidic FGF. J Biol Chem. 1992; 267: 3343-3350. 22 Ito H, Hiroe M, Hirata Y, et al.: Insulin-like growth factor-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993; 87: 1715-1721. 23 Lavandero S, Foncea R, Pérez V, et al.: Effect of inhibitors of signal transduction on IGF-1-induced protein synthesis associated with hypertrophy in cultured neonatal rat ventricular myocytes. FEBS Lett. 1998; 422: 193-196. 24 Ebensperger R, Acevedo E, Melendez, et al.: Selective increase in cardiac IGF-1 in rat model of ventricular hypertrophy. Biochem Biophys Res Commun. 1998; 243: 20-24. 25 Sugden PH, Fuller SJ: Regulation of protein turnover in skeletal and cardiac muscle. Biochem J. 1991; 273: 21-37. 26 Hannan RD, Rothblum LI: Regulation of ribosomal DNA transcription during neonatal cardiomyocyte hypertrophy. Cardiovasc Res. 1995; 30: 501-510. 27 Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25): 2981-2988. 28 Cameron VA, Ellmers LJ: Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology. 2003; 144(6): 2191-2194. 29 Calderone A, Takahashi N, Izzo NJ Jr, et al.: Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocytes phenotypes and differential induction of peptide growth factor mRNAs. Circulation. 1995; 92: 2385-2390. 30 Frey N, Olson EN: Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol. 2003; 65 45-6579. 31 Jalili T, Takeishi Y, Walsh RA: Signal transduction during cardiac hypertrophy: the role of Gαq, PLC β I, and PKC. Cardiovasc Res. 1999; 44: 5-9. 32 Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998; 76 : 725-746. 33 Simpson PC: Beta-PKC and hypertrophic signaling in human heart failure. Circulation. 1999; 99: 334-337. 34 Disatnik MH, Buraggi G, Mochly-Rosen D: Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994; 210: 287-297. 35 Bowling N, Walsh RA, Song G, et al.: Increased protein kinase C activity and expression of Ca-sensitive isoforms in the failing human heart. Circulation. 1999; 99: 384-391. 36 Kerkelä R, Ilves M, Pikkarainen S, et al.: Identification of PKCα isoform specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides. Mol Pharmacol. 2002; 62: 1482-1492. 37 Gu X, Bishop SP: Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res.1994; 75: 926-931. 38 Walsh MP, Horowitz A, Clément-Chomienne O, et al.: Protein kinase C mediation of Ca2+-independent contractions of vascular smooth muscle. Biochem Cell Biol. 1996; 74: 485-502. 39 Castagna M, Takai Y, Kaibuchi K, et al.: Direct activation of calcium-activated, phopholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982; 257: 7847-7851. 40 Pucéat M, Vassort G: Signalling by protein kinase C isoforms in the heart.Mol Cell Biochem. 1996; 157: 65-72. 41 Brutsaert DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003; 83: 59-115. 42 Parodi O, DeMaria R, Oltrona L, et al.: Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation. 1993; 88: 509-522. 43 Opherk D, Schwartz F, Mall G, et al.: Coronary dilatory capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. Am J Cardiol. 1983; 51: 1657-1662. 44 Nitenberg A, Foult JM, Blanchet F, et al.: Multifactorial determinants of reduced coronary flow reserve after dipyridamol in dilated cardiomyopathy. Am J Cardiol. 1985; 55: 748-754. 45 Traverse JH, Melchert P, Pierpont GL, et al.: Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. Circ Res. 1999; 84: 401-408. 46 Spinale FG, Tanaka R, Crawford FA, et al.: Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation. 1992; 85: 717-729. 47 Shannon RP, Komamura K, Shen Y, et al.: Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure.Am J Physiol. 1993; 265: H801-H809. 48 Anversa P, Olivetti G, Melissari M, et al.: Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol. 1980; 12: 781-795. 49 Davis D, Baily R, Zelis R: Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol. 1988; 254: E760-E766. 50 Hasking GJ, Esler MD, Jennings GL, et al.: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986; 73: 615-620. 51 Rodeheffer RJ, Lerman A, Heublein DM, et al.: Increased plasma concentration of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992; 67 : 719-724. 52 Margulies KF, Hildebrand FL Jr, Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation. 1990; 82: 2226-2230. 53 Wei CM, Lerman A, Rodeheffer RJ, et al.: Endothelin in human congestive heart failure. Circulation. 1994; 89: 1580-1586. 54 Dzau VJ, Colucci WS, Hollenberg NK, et al.: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981; 93 : 645-651. 55 Goldsmith SR, Francis GS, Cowley AW, et al.: Increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol. 1983; 1: 1385-1390. 56 Heart Disease. A Textbook of Cardiovascular Medicine 5th Ed.

Philadelphia

W.B. Saunders Company. 1996; 394-420. 57 Atlas SA, Kleinert HD, Camargo MJ, et al.: Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature. 1984; 309: 717-719. 58 Marcus LS, Hart D, Packer M, et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled randomized crossover trail. Circulation. 1996; 94: 3184-3189. 59 Melo LG, Veress AT, Ackerman U, et al.: Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept. 1999; 79: 109-115. 60 Silberbach M, Gorenc T, Hershberger RE, et al.: Extracellular signal-regulated protein kinase activation is required for the antihypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem. 1999; 274(35): 24858-24864. 61 Horio T, Nishikimi T, Yoshihara F, et al.: Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000; 35(1): 19-24. 62 Calderone A, Thaik CM, Takahashi N, et al.: Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998; 101(4): 812-818. 63 N akaoka H, Imitaka K, Amano M, et al.: Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med. 1985; 313: 892-893. 64 Tikkanen J, Fyhrquist F, Metsarinne K, et al.: Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy subjects. Lancet. 1985; ii : 66-69. 65 Burnett Jr JC, Kao PC, Hu DC, et al.: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986; 231: 1145-1147. 66 Clerico A, Iervasi G, Del Chicca MG, et al.: Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric essay in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998; 21: 170-179. 67 Wijbenga JAM, Balk AHMM, Jonkman FAM, et al.: Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Hear Failure. 1999; 1: 51-58. 68 Habib F, Dukta D, Crossman D, et al.: Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet. 1994; 344: 371-373. 69 Kitamura K, Kangawa K, Kawamoto M, et al.: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553-560. 70 Kobayashi K, Kitamura K, Etoh T, et al.: Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J. 1996; 131: 994-998. 71 Nishikimi T, Saito Y, Kitamura K, et al.: Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995; 26: 1424-1431. 72 Cheng C-P, Onishi K, Othe N, et al.: Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol. 1998; 31: 1679-1686. 73 Dzau VJ, Packer M, Lilly LS, et al.: Prostaglandins in severe congestive heart failure. N Engl J Med. 1984; 310: 347-352. 74 Kirsch B: Electron microscopy of the atrium of the heart. Exp Med Surg. 1956; 14: 99-111. 75 de Bold AJ, Borenstein HB, Veress AT, et al.: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 8: 89-94. 76 Kangawa K, Matsuo H: Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 1984; 118: 131-139. 77 Flynn TG, de Bold ML, de Bold AJ: The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun. 1983; 117: 859-865. 78 Sudoh T, Kangawa K, Minamino N, et al.: A new natriuretic peptide in porcine brain. Nature. 1988; 332: 78-81. 79 Kambayashi Y, Nakao K, Mukoyama M, et al.: Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990; 259: 341-345. 80 Schulz-Knappe P, Forssmann K, Herbst F, et al.: Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr. 1988; 66 : 752-759. 81 Totsune K, Takahashi K, Murakami O, et al.: Natriuretic peptides in the human kidney. Hypertension. 1994; 24: 758-762. 82 Meyer M, Richter R, Brunkhorst, et al.: Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol. 1996; 271: F489-F497. 83 Sudoh T, Minamino N, Kangawa K, et al.: C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168: 863-870. 84 Brown J, Zuo Z: C-type natriuretic peptide and atrial natriuretic peptide receptors of rat brain. Am J Physiol. 1993; 264: R513-R523. 85 Ueda S, Minamino N, Aburaya M, et al.: Distribution and characterization of immunoreactive porcine C-type natriuretic peptide. Biochem Biophys Res Commun. 1991; 175: 759-767. 86 Komatsu Y, Nakao K, Suga S, et al.: C-type natriuretic peptide (CNP) in rats and humans. Endocrinology. 1991; 129: 1104. 87 Banks M, Wei C-M, Kim Ch, et al.: Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol. 1996; 271: H1907-H1911. 88 Schweitz H, Vigne P, Moinier D, et al.: A new member of the natriuretic peptide family is present in the venom of the green mamba (dendroaspis angusticeps). J Biochem. 1992; 267: 13928-13932. 89 Schirger JA, Heublein DM, Chen HH, et al.: Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999; 74: 126-130. 90 Inagami T, Misono Ks, Fukumi H, et al.: Structure and physiological actions of rat atrial natriuretic factor. Hypertension. 1987; 10(5): 1113-1117. 91 Nakao K, Ogawa Y, Suga S, et al.: Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992; 10: 1111-1114. 92 Itoh H, Sagawa N, Hasegawa M, et al.: Expression of biologically active receptors for natriuretic peptides in the human uterus during pregnancy. Biochem Biophys Res Commun. 1994; 203: 206-207. 93 Boomsma F, Wijbenga A, Jonkman F, et al.: Neurohormonal activation adressed and at peak exercise in patients with congestive heart failure (NYHA class 1-3). J Hypertens. 1998; 16(suppl 2): S230, (Abstract). 94 Konrad EM, Thibault G, Schiffrin EL, et al.: Atrial natriuretic factor receptor subtypes in the rat central nervous system. Hypertension. 1991; 17: 1144-1151. 95 Drewett JG, Garbers DL: The family of guanylyl cyclase receptors and their ligands. Endocr Rev. 1994; 15(2): 135-162. 96 Maack T, Suzuki M, Almeida FA, et al.: Physiological role of silent receptors of atrial natriuretic factor. Sience. 1987; 238: 675-678. 97 Wilcox JN, Augustine A, Goeddel DV, et al.: Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol. 1991; 11(7): 3454-3462. 98 Hollister AS, Rodeheffer RJ, White FJ, et al.: Clearance of natriuretic factor by lung, liver, and kidney in human subjects and the dog. J Clin Invest. 1989; 83(2): 623-628. 99 Cerra MC: Cardiac distribution of the binding sites for natriuretic peptides in vertebrates. Cardioscience. 1994; 5(4): 215-224. 100 Matsukawa N, Grzesik WJ, Takahashi N, et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 1999; 96(13): 7403-7408. 101 Schulz S, Singh S, Bellet RA, et al: The primary structure of a plasma membane guanylate cyclase demonstrates diversity within this new receptor family. Cell. 1989; 58: 1155-1162. 102 Tremblay J, Desjardins R, Hum D, et al.: Biochemistry and physiology of the natriuretic peptide receptor guanylyl cylases. Mol Cell Biochem. 2002; 230: 31-47. 103 Koller KJ, Lowe DG, Bennett GL: Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991; 252: 120-123. 104 Hirata Y, Emori T, Ohta K, et al.: Vasoconstrictor-induced heterologous down-regulation of vascular atrial natriuretic peptide receptor. Eur J Pharmacol. 1989; 164: 603-606. 105 Misono KS: Atrial natriuretic factor binding to its receptor is dependent on chloride concentration: A possible feedback-control mechanism in renal salt regulation. Circ Res. 2000; 86: 1135-1139. 106 Anand-Srivastava MB: Atrial natiuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens. 1997; 15: 815-826. 107 Suga S, Nakao K, Hosoda K, et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992; 130(1): 229-239. 108 Nussenzveig DR, Lewicki JA, Maack T: Cellular mechanism of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem. 1990; 265: 20952-20958. 109 Matsukawa N, Grzesik WJ, Takahashi, et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of natriuretic peptide system. Proc Natl Acad Sci USA. 1999; 96: 7403-7408. 110 Kashiwagi M, Katafuchi T, Kato A, et al.: Cloning and properties of a novel natriuretic peptide receptor, NPR-D. Eur J Biochem. 1995; 233: 102-109. 111 Ravichandran LV, Johns RA: Upregulation of endothelial nitric oxide synthase expression by cyclic guanosine 3´-5´monophosphate. FEBS Lett. 1995; 374: 295-298. 112 Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature. 1986; 324: 473-476. 113 Sonnenberg H, Honrath U, Chong CK, et al.: Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol. 1986; 250: F963-F966. 114 McMurray J, Seidelin PH, Struthers AD: Evidence for a proximal and distal nephron action of atrial natriuretic factor in man. Nephron. 1989; 51: 39-43. 115 Dillingham MA, Anderson RJ: Inhibition of vasopressin action by atrial natriuretic factor Science. 1986; 231: 1572-1573. 116 Volpe M, Odell G, Kleinert HA, et al.: Effect of atrial natriuretic factor (ANF) on blood pressure, renin and aldosterone in Goldblatt hypertension. Hypertension. 1985; 7(suppl 1): 43-48. 117 Cuneo RC, Espiner EA, Nicholls MG, et al.: Effect of physiological levels of atrial natriuretic peptide on hormone secretion: Inhibition of angiotensin-induced aldosterone secretion and renin release in normal man. J Clin Endocrinol Metab. 1987; 65: 765-772. 118 Pfaffendorf M: Atriales natriuretisches peptid als angiotensin-II-antagonist. Med Mol Pharm. 1992; 15: 169-178. 119 Levin ER, Gardner DG, Samson WK: Mechanisms of disease: natriuretic peptide. N Engl J Med. 1998; 339: 321-328. 120 Calderone A: The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial inducible nitric oxide synthase Heart Failure. Reviews. 2003; 8: 55-70. 121 Wijeyaratne CN, Moult PJA: The effect of alpha human atrial natriuretic peptide on plasma volume in vascular permeability in normotensive subjects. J Clin Endocrinol Metab. 1993; 76: 343-346. 122 Morishita R, Gibbons GH, Pratt RE, et al.: Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest. 1994; 94(2): 824-829. 123 Hutchinson HG, Trindade PT, Cunanan DB, et al.: Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res. 1997; 35(1): 158-167. 124 Suhasini M, Li H, Lohmann SM, et al.: Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol Cell Biol. 1998; 18(12):6983-6994. 125 Cao L, Gardner DG: Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995; 25: 227-234. 126 Redondo J, Bishop JE, Wilkins MR, et al.: Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen sythesis by adult cardiac fibroblasts. J Pharmacol. 1998; 124(7): 1455-1462. 127 Sengenes C, Berlan M, De Glisezinski I, et al.: Natriuretic peptides: A new lipolytic pathway in human adipocytes. FASEB J. 2000; 14: 1345-1351. 128 Sugimoto T, Kikkawa R, Haneda M, et al.: Atrial natriuretic peptide inhibits endothelin-1-induced activation of mitogen-activated protein kinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 1993; 195(1): 72-78. 129 Isono M, Haneda M, Maeda S, et al.: Atrial natriuretic peptide inhibits endothelin-1-induced activation of JNK in glomerular mesangial cells. Kidney Int. 1998; 53(5): 1133-1142. 130 Biesiada E, Razandi M, Levin VER: Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem. 1996; 271(31): 18576-18581. 131 Hu RM, Levin ER: Astrocyte growth is regulated by neuropeptides through Tis8 and basic fibroblast growth factor. J Clin Invest. 1994; 93(4): 1820-1827. 132 Anand-Srivastava MB, Srivastava AK, Cantin M: Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cylase/cAMP signal transduction system. J Biol Chem. 1990; 265: 8566-8572. 133 J ohnson BG, Trachte GJ, Drewett JG: Neuromodulatory effect on the atrial natriuretic factor clearance receptor binding peptide, cANF(4-23)-NH_2 in rabbit isolated vasa deferentia. J Pharmacol Exp Ther. 1991; 256: 720-726. 134 Maki M, Takayanagi R, Misono KS, et al.: Structure of rat atrial natriuretic factor precursor deduced from cDNA sequence. Nature. 1984; 309: 222-224. 135 Seidman CE, Duby AD, Choi E: The structure of rat preproatrial natriuretic factor as defined by complementary DNA clone. Science. 1984; 225: 324-326. 136 Yamanaka M, Greenberg B, Johnson L, et al.: Cloning and sequence analysis of the cDNA for the rat atrial natriuretic factor precursor. Nature. 1984; 309: 719-722. 137 Zivin RA, Condra JH, Dixon RAF, et al.: Molecular cloning and characterization of DNA sequences encoding rat and human atrial natriuretic factors. Proc Natl Acad Sci USA. 1984; 81: 6325-6329. 138 Oikawa S, Imai M, Ueno A, et al.: Cloning and sequence analysis of cDNA encoding precursor for human atrial natriuretic polypeptide. Nature. 1984; 309: 724-726. 139 Voulteenaho O, Arjamaa O, Ling N: Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun. 1985; 129: 82-88. 140 Day ML, Schwartz D, Wiegand RC, et al.: Ventricular atriopeptin unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension. 1987; 9: 485-491. 141 Stockmann PT, Will DH, Sides SD, et al.: Reversible induction of right ventricular atriopeptin synthesis in hypertrophy due to hypoxia. Circ Res. 1988; 63: 207-213. 142 Newman TM, Severs NJ: Arrested exocytosis of atrial secretory granules. J Mol Cell Cardiol. 1990; 22: 771-786. 143 Gilloteaux J, Jennes L, Menu R, et al.: Ultrastructural immunolocalization of the atrial natriuretic factor pathway in fetal neonatal and adult Syrian hamsters: from the atrial cardiomyocytes in the circulation via the endocardium, atrial capillaries and epicardium. J Submicrosc Cytol Pathol. 1991; 23: 75-91. 144 Yan W, Wu F, Morser J, et al.: Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. PNAS. 2000; 97: 8525-8529. 145 Vesely DL: Atrial natriuretic peptides in pathological diseases. Cardiovasc Res. 2001; 51: 647-658. 146 Vesely DL: Atrial natriuretic peptides in the diagnosis and treatment of congestive heart failure. CHF. 1999; 5: 171-179,183. 147 Vesely DL: Congestive heart failure update: new cardiac peptides in diagnosis and treatment. Consultant. 2000; 40: 253-263. 148 Nemer M, Lavigne JP, Droun J, et al.: Expression of atrial natriuretic factor gene in heart ventricular tissue. Peptides. 1986; 7: 1147-1152. 149 Ruskoaho H, Thölken H, Lang RE: Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts. Pflugers Arch. 1986; 407: 170-174. 150 de Bold AJ, Bruneau BG, Kursoki de Bold ML: Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996; 31: 7-18. 151 Laine M, Arjamaa O, Vuolteenaho O, et al.: Block of stretch-activated atrial natriuretic peptide secretion by gadolinium in isolated rat atrium. J Physiol. 1994; 480: 553-561. 152 Laine M, Weckstrom M, Vuolteenaho O, et al.: Effect of ryanodine on atrial natriuretic peptide secretion by contracting quiescent rat atrium. Pflug Arch Eur J Physiol. 1994; 426: 276-283. 153 Katoh S, Toyama J, Aoyama M, et al.: Mechanisms of atrial natriuretic peptide (ANP) secretion by rat hearts perfused in vitro-Ca2(+)-dependent signal transduction for ANP release by mechanical stretch. Jpn Circ J. 1990; 54: 1283-1294. 154 Kuroski-de Bold ML, de Bold AJ: Stretch-secretion coupling in atrial cardiocytes. Dissociation between atrial natriuretic factor release and mechanical activity. Hypertension. 18(Suppl.III): 169-178. 155 McDonough PM, Glembotski CC: Induction of atrial natriuretic factor and myosin light chain-2 gene expression in cultured ventricular myocytes by electrical stimulation of contraction. J Biol Chem. 1992; 267: 11665-11668. 156 Gardner DG, Wirtz H, Dobbs LG: Stretch-dependent regulation of atrial peptide synthesis and secretion in cultured atrial cardiomyocytes. Am J Physiol. 1992; 263: E239-E244. 157 Ambler SK, Leite MF: Regulation of atrial natriuretic peptide secretion by alpha 1-adrenergic receptors: the role of different second messenger pathways. J Mol Cell Cardiol. 1994; 26: 391-402. 158 Wu SQ, Kwan CY, Tang F: The effect of aging on ANP levels in the plasma, heart, and brain of rats. J Gerontol Ser A. 1997; 52 : B250-B254. 159 Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993; 132: 1961-1970. 160 Schiebinger RJ, Greening KM: Interaction between stretch and hormonally stimulated atrial natriuretic peptide secretion. Am J Physiol. 1992; 262: H78-H83. 161 Skvorak JP, Nazian SJ, Dietz JR: Endothelin acts as a paracrine regulator of stretch-induced atrial natriuretic peptide release. Am J Physiol. 1995; 269: R1093-R1098. 162 Skvorak JP, Dietz JR: Endothelin and nitric oxide interact to regulate stretch induced ANP-Secretion. Am J Physiol. 1997; 273: R301-R306. 163 Ruskoaho H, Vakkuri O, Arjamaa O, et al.: Pressor hormones regulate atrial-stretch-induced release of atrial natriuretic peptide in the pithed rats. Circ Res. 1989; 64: 482-492. 164 Thibault G, Doubell AF, Garcia R, et al.: Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. Circ Res. 1994; 74: 460-470. 165 Irons CE, Murray SF, Glembotski CC: Identification of the receptor subtype responsible for endothelin-mediated protein kinase C activation and atrial natriuretic factor secretion from atrial myocytes. J Biol Chem. 1993; 268: 23417-23421. 166 Leite MF, Page E, Ambler SK: Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: desensitization and receptor subtype. Am J Physiol. 1994. 267: H2193-H2203. 167 Schiebinger RJ, Gomez-Sanchez CE: Endothelin: a potent stimulus of atrial natriuretic peptide secretion by superfused rat atria and its dependency on calcium. Endocrinology. 1990; 127: 119-125. 168 Sei CA, Glembotski CC: Calcium dependence of phenylephrine-, endothelin-, and potassium chloride-stimulated atrial natriuretic factor secretion from long term primary neonatal rat atrial cardiocytes. J Biol Chem. 1990; 265: 7166-7172. 169 Fukuda Y, Hirata Y, Yoshimi H, et al.: Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun. 1988; 155: 167-172. 170 Lew RA, Baertschi AJ: Endothelium-dependent ANF secretion in vitro. Am J Physiol. 1992; 263: H1071-H1077. 171 Irons CE, Sei CA, Hidaka H, et al.: Proteinkinase C and calmodulin kinase are required for endothelin-stimulated atrial natriuretic factor secretion from primary atrial myocytes. J Biol Chem. 1992; 267: 5211-5216. 172 Gardner DG, Newman ED, Nakamura KK, et al.: Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes. Am J Physiol. 1991; 261: E177-E182. 173 Pitkanen M, Mantymaa P, Ruskoaho H: Staurosporine, a protein kinase C inhibitor, inhibits atrial natriuretic peptide secretion induced by sarafotoxin, endothelin and phorbol ester. Eur J Pharmacol. 1991; 195: 307-315. 174 Schiebinger RJ, Parr HG, Cragoe EJ Jr: Calcium: its role in alpha 1-adrenergic stimulation of atrial natriuretic peptide secretion. Endocrinology. 1992; 130: 1017-1023. 175 Lachance D, Garcia R, Gutkowska J, et al.: Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces. Biochem Biophys Res Commun. 1986; 135: 1090-1098. 176 Van de Bent V, Church DJ, Vallotton MB, et al.: [Ca2+] i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol. 1994; 266: H597-H605. 177 Matsubara H, Hirata Y, Yoshimi H, et al. Role of calcium and protein kinase C in ANP secretion by cultured rat cardiocytes. Am J Physiol. 1988; 255: H504-H509. 178 Soualmia H, Barthelemy C, Masson F, et al.: Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J Cardiovasc Pharmacol. 1997; 29: 605-611. 179 Soualmia H, Masson F, Barthelemy C, et al.: Cellular mechanism of angiotensin II-induced atrial natriuretic peptide release in rat right atrial tissue. Life Sci. 1996; 58: 1621-1629. 180 Shubeita HE, Martinson EA, Van Bilsen M, et al.: Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by proteinkinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1992; 89: 1305-1309. 181 Bogoyevitch MA, Glennon PE, Sugden PH: Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activity in ventricular cardiomyocytes. FEBS Lett. 1993; 317: 271-275. 182 Zongazo MA, Carayon MA, Masson F, et al.: Effects of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria. Eur J Pharmacol. 1991; 209: 45-55. 183 Azizi C, Carayon A, Masson F, et al.: Mechanisms of isoproterenol-induced atrial natriuretic peptide release from superfused rabbit atria. Am J Physiol. 1993; 265: H1283-H1288. 184 Church DJ, Van der Bent V, Vallotton MB, et al.: Role of prostaglandin-mediated cyclic AMP formation in protein kinase C-dependent secretion of atrial natriuretic peptide in rat cardiomyocytes. Biochem J. 1994; 303: 217-225. 185 Leskinen H, Vuolteenaho O, Leppaluoto J, et al.: Role of nitric oxide on cardiac hormone secretion: Effect of N(G)-Nitro-L-arginine methyl ester on atrial natriuretic peptide and brain natriuretic peptide release. Endocrinology. 1995; 136: 1241-1249. Melo LG, Sonnenberg H: Effect of nitric oxide inhibition on secretion of atrial natriuretic factor in isolated rat heart. Am J Physiol. 1996; 270: H306-H311. 187 Sato A, Canny BJ, Autelitano DJ: Adrenomedullin stimulates cAMP accumulation and inhibits atrial natriuretic peptide gene expression in cardiomyocytes. Biochem Biophys Res Commun. 1997; 230: 311-314. 188 Winters CJ, Sallman AL, Baker BJ, et al.: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation. 1989; 80: 438-449. 189 Daggubati S, Parks JR, Overton RM, et al.: Adrenomedullin, endothelin, neuropeptide Y., atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res. 1997; 36: 246-255. 190 Hall C, Rouleau JL, Moye L, et al.: N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994; 89: 1934-1942. 191 Lerman A, Gibbons RJ, Rodeheffer et al.: Circulating N-terminal atrial natriuretic paptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993; 341: 1105-1109. 192 Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endocrine Reviews. 2003; 24: 341-356. 193 Morita H, Tanaka I, Oda T, et al.: Atrial natriuretic peptide messenger RNA and peptide in rats with aortic valve insufficiency. Peptides. 1990; 11(4): 843-847. 194 Cantin M, Thibault G, Ding JF, et al.: ANF in experimental congestive heart failure. Am J Pathol. 1988; 130: 552-568. 195 Wong NL, Wong EF, Hu DC: Atrial natriuretic factor release in cardiomyopathic hamsters. Cardiology. 1992; 80: 12-17. 196 Tsuchimochi H, Yazaki Y, Ohno H, et al.: Ventricular expression of atrial natriuretic peptide. Lancet. 1987; 2: 336-337. 197 Thibault G, Nemer M, Drouin J, et al.: Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamster with heart failure. Circ Res. 1989; 65: 71-82. 198 Takahashi T, Allen PD, Izumo S: Expression of A-, B-, C-type natriuretic peptide genes in failing and developing human ventricles: correlation with expression of the Ca2+-ATPase gene. Circ Res. 1992; 71: 9-17. 199 Feldman AM, Ray PE, Silan CM, et al.: Selective gene expression in failing human heart. Circulation. 1991; 83: 1866-1872. 200 Saito Y, Nakao K, Arai H, et al.: Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989; 83: 298-305. 201 Biollaz J, Callahan LT, Nussberger J, et al.: Pharmacokinetics of synthetic atrial natri>uretic peptides in normal men. Clin Pharmacol Ther. 1987; 41: 671-677. 202 Charles CJ, Espiner EA, Nicholls MG, et al.: Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996; 271: R373-R380. 203 Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990; 24: 430-432. 204 Langenickel T, Pagel I, Buttgereit J, et al.: Rat corin gene: Molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004; 287(4): H1516-H1521. 205 Redfield MM, Edwards BS, McGoon MD, et al.: Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation. 1989; 80(3): 651-657. 206 Tomanek RJ, Torry RJ: Growth of the coronary vasculature in hypertrophy: mechanisms and model dependence. Cell Mol Biol Res. 1994; 40: 129-136. 207 Scriven TA, Burnett Jr JC: Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 1985; 72: 892-897. 208 Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986; 78: 1362-1374. 209 Potter LR, Garbers DL: Protein kinase C-dependent desentization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J Biol Chem. 1994; 269: 14636-14642. 210 Volpe M, Tritto C, DeLuca N, et al.:Failure of Atrial Natriuretic Factor to Increase with Saline Load in Patients with Dilated Cardiomyopathy and Mild Heart Failure. J Clin Invest. 1991; 88: 1481-1489. 211 Volpe M, Tritto C, DeLuca N, et al.: Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation. 1992; 86(6): 1800-1809. 212 Sata N, Tanaka Y, Suzuki S, et al.: Effectiveness of Angiotensin-Converting Enyzme Inhibitor or Angiotensin II Receptor Blocker on Atrial Natriuretic Peptide. Circ J. 2003; 67: 1053-1058. 213 Tran KL, Lu X, Lei M, et al.: Up-regulation of Corin Gene Expression in Hypertrophic Cardiomyocytes and Failing Myocardium.Am J Physiol Heart Circ Physiol. 2004; 287(4): H1625-H1631. 214 Drexler H, Hanze J, Finckh M, et al.: Atrial natriuretic peptide in a rat model of cardiac failure. Atrial and ventricular mRNA, atrial content, plasma levels, and effect of volume loading. >Circulation. 1989; 79(3): 620-633. 215 Mendez RE, Pfeffer JM, Ortola FV, et al.: Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction. Am J Physiol. 1987; 253(6Pt2): H1449-H1455. 216 Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960; 5: 370-382. 217 Fujiwara T, Fujiwara H, Takemura G, et al.: Expression and distribution of atrial natriuretic polypeptide in the ventricles of children with myocarditis and/or myocardial infarction secondary to Kawasaki disease: immunohistochemical study. Am Heart J. 1990; 120: 612-618. 218 Takemura G, Fujiwara H, Mukoyama M, et al.: Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy. Circulation. 1991; 83: 181-190. 219 Currie MG, Oehlenschlager WF, Kurtz DT: Profound elevation of ventricular and pulmonary atriopeptin in a model of heart failure. Biochem Biophys Res Commun. 1987; 148(3): 1158-1164. Edwards BS, Ackermann DM, Lee M, et al.: Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest. 1988; 81: 82-87. 221 Franch HA, Dixon RA, Blaine EH, et al.: Ventricular atrial natriuretic factor in the cardiomyopathic hamster model of congestive heart failure. Circ Res. 1988; 62: 31-36. 222 Tune JD, Richmond KN, Gorman MW, et al.: Control of coronary blood flow during exercise. Exp Biol Med. 2002; 227(4): 238-250. 223 Larsen TH, Myking O, Lillehaug Jr, et al.: Inhibition and down regulation of protein kinase C in cultured atrial myocytes: effects on distribution of specific granules and secretion of atrial natriuretic peptide. Mol Cell Endocrinol. 1993; 94:173-81. 224 Rodriquez-Pena A, Rozengurt E: Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. Biochem Biophys Res Commun. 1984; 120(3): 1053-1059. 225 Ballester R, Rosen OM: Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate. J Biol Chem. 1985; 260(28): 15194-15199. 226 Hepler JR, Earp HS, Harden TK: Long-term phorbol ester treatment downregulates protein kinase C and sensitizes the phosphoinositide signaling pathway to hormone and growth factor stimulation. Evidence for a role of protein kinase C in agonist induced desensitization. J Biol Chem. 188 2; 63(16): 7610-7619. 227 Pfeilschifter J, Ochsner M, Whitebread S, et al.: Down-regulation of protein kinase C potentiates angiotensin II-stimulated polyphosphoinositide hydrolysis in vascular smooth-muscle cells. Biochem J. 1989; 262(1): 285-291. 228 Kumar R, Cartledge WA, Lincoln TM, et al.: Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells. Hypertension. 1997; 29(part 2): 414-421. 229 Uusimaa P, Ruskoaho H, Leppaluoto J, et al.: Cytosolic Ca2+ during atrial natriuretic peptide secretion from cultured neonatal cardiomyocytes. Mol Cell Endocrinol. 1990; 73: 253-263. 230 Ruskoaho H, Toth M, Ganten D, et al.: The phorbol ester induced atrial natriuretic peptide secretion is stimulated by forskolin and BAY K8644 and inhibited by 8-bromo-cyclicGMP. Biochem Biophys Res Commun. 1986; 139(1): 266-274. 231 Ruskoaho H, Vuolteenaho O, Leppäluoto J: Phorbol esters enhance stretch-induced atrial natriuretic peptide secretion. Endocrinology. 1990; 127: 2445-2455. 232 Leskinen H, Vuolteenaho O, Toth M, et al.: Atrial natriuretic peptide (ANP) inhibits its own secretion via ANP_A receptors: altered effect in experimental hypertension. Endocrinology. 1997; 138(5): 1893-1902. 233 van Bibber R, Traub O, Kroll K, et al.: EDRF and norepinephrine-induced vasodilation in the canine coronary circulation. Am J Physiol. 1995; 268(Heart Circ Physiol 37): H1973-H1981. 234 Hirata K-I, Kuroda R, Sakoda T, et al.: Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension. 1995; 25: 180-185. 235 Church DJ, Braconi S, Van der Bent V, et al.: Protein kinase C-dependent prostaglandin production mediates angiotensin II-induced atrial-natriuretic peptide release. Biochem J. 1994; 298: 451-456. 236 Ruskoaho H: Atrial Natriuretic Peptide: Synthesis, Release, and Metabolism. Pharmacological Reviews. 1992; 44(4):479-602. 237 Willenbrock R, Scheuermann M, Thibault G, et al.: Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt. Cardiovasc Res. 1999; 42: 733-742. 238 Qing G, Garcia R: Characterization of plasma and tissue atrial natriuretic factor during development of moderate high output heart failure in the rat. Cardiovasc Res. 1993; 27: 464-470. 239 Garcia R, Lachance D, Thibault G: Atrial natriuretic factor release and natriuresis in rats with high-output heart failure. Am J Physiol. 1990; 259(5Pt2): H1374-H1379. 240 Langenickel T, Pagel I, Höhnel K, et al.: Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol. 2000; 278: H1500-H1506. 241 Brown LA, Nunez D, Wilkins MR: Differential Regulation of Natriuretic Peptide Receptor Messenger RNAs during the Development of Cardiac Hypertrophy in the Rat. J Clin Invest. 1993; 92: 2702-2712. 242 Forssmann WG, Richter R, Meyer M: The endocrine heart and natriuretic peptides: histochemistry cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol. 1998; 110:335-357. 243 Zink R, Heiny o, Steiert H: Bedienungsanleitung zur Apparatur isoliertes Herz Größe 3, Typ 830, Version 1.0. 1994; 16.